Revolutionizing Genome Editing with Bio-Techne
Bio-Techne Corporation (NASDAQ: TECH) takes a significant step forward in life science research by unveiling its GMP Transposase mRNA for the TcBuster™ non-viral genome engineering system. This launch heralds a new era in the production of immune cell and stem cell-based therapies, crucial in today’s medical landscape.
Advantages of the TcBuster System
Researchers have already embraced the TcBuster System for its capability to facilitate large genetic modifications across various cell types. The recent introduction of GMP-grade transposase sets a clear path for clinical applications in gene-editing therapies, notably those involved in CAR-T and TCR generation, thereby enhancing treatment options for patients.
Enhanced Non-Viral Methodology
The non-viral nature of the TcBuster System presents numerous advantages compared to traditional lentivirus techniques used in cell therapy development. Thanks to innovative protein engineering, the system features an advanced hyperactive enzyme that enables the simultaneous delivery of multiple genes from a GMP transposon, ensuring top-notch editing efficiency and a lower risk of insertional mutagenesis.
Streamlining Cell Therapy Development
By eliminating the need for cumbersome viral clearance methods, the TcBuster system reduces overall time-to-market and decreases costs for developers in the field of cell therapy. This enables faster accessibility of critical treatments to those in need, something that is paramount in impactful medical research.
Dependable Supply Chain and Scalability
Bio-Techne’s robust supply chain encompasses both research-use-only (RUO) and GMP-grade reagents, allowing seamless transitions from research to clinical and eventually to commercial applications. This reliability positions Bio-Techne as a trusted partner for researchers and companies scaling their therapies.
Support from Experts
“Our customers rely on us to help de-risk their cell therapy manufacturing programs and support their scale-up to clinical trials and commercial manufacturing,” states Will Geist, President of Bio-Techne's Protein Science Segment. With the new GMP version of the TcBuster system, the company anticipates that cell therapy developers will gain a substantial technical advantage in gene editing without encountering the challenges posed by traditional viral delivery methods.
Expansive Applications of TcBuster
The TcBuster system is engineered to work with various cell types, offering versatility for autologous CAR-T or TCR manufacturing, allogeneic NK therapies, and even bioprocessing cell lines for the production of therapeutic biologics. This adaptability ensures that Bio-Techne remains at the forefront of developmental medicine, meeting the diverse needs of researchers and clinicians alike.
About Bio-Techne Corporation
Headquartered globally, Bio-Techne Corporation (NASDAQ: TECH) is dedicated to providing innovative tools and bioactive reagents that empower research and clinical diagnostic sectors. Recognized for its extensive portfolio that spans hundreds of thousands of products, Bio-Techne plays a vital role in shedding light on biological processes and advancing drug discovery efforts. In fiscal 2024, the company reported approximately $1.2 billion in net sales, underscoring its substantial impact and commitment to the scientific community.
Frequently Asked Questions
What is the TcBuster non-viral genome engineering system?
The TcBuster system is an advanced non-viral method for genome editing, allowing delivery of large genetic modifications across various cell types.
What makes the GMP-grade TcBuster significant?
The GMP-grade TcBuster ensures safe and effective use in clinical applications, vital for developing cell therapies like CAR-T.
How does the TcBuster system compare to viral methods?
Unlike viral methods, the TcBuster system eliminates the need for viral clearance, simplifying the development process while reducing costs.
Who can benefit from using the TcBuster system?
Researchers and pharmaceutical companies involved in cell therapies and bioprocessing can benefit significantly from the reliable performance of the TcBuster system.
What is Bio-Techne's market presence?
Bio-Techne has a global presence with around 3,100 employees, reflecting its role as a leader in the life sciences sector.
